Home Increased plasma concentrations of tumour markers in the absence of neoplasia
Article
Licensed
Unlicensed Requires Authentication

Increased plasma concentrations of tumour markers in the absence of neoplasia

  • Jaume Trapé EMAIL logo , Xavier Filella , Montse Alsina-Donadeu , Lluïsa Juan-Pereira , Àngels Bosch-Ferrer , Raül Rigo-Bonnin and Oncology Section of the Catalan Association of Clinical Laboratory Science
Published/Copyright: September 6, 2011

Abstract

Tumour markers are a very heterogeneous group of molecules that are generally found in very small concentrations in the plasma and serum of healthy individuals. In the process of neoplastic differentiation the cell can synthesize, release, or induce synthesis of other cells, thus increasing their concentration in plasma and serum. These substances may also increase their plasma concentration in patients without cancer due to processes that increase the release or reduce catabolism, and so give rise to false positives. An understanding of the main physiopathological processes that increase the concentrations of these substances could improve our interpretation of tumour markers and their clinical application. In this study we review the physiopathological processes that may increase the plasma concentrations of tumour markers. We performed a bibliography review in PubMed, searching for causes of false positives for the following tumour markers: α-Fetoprotein, CA 125, CA 15-3, CA 19-9, CA 72-4, carcinoembryonic antigen, CYFRA 21-1, squamous cell carcinoma, prostatic specific antigen, β2-microglobulin, choriogonadotropin (β chain), chromogranin A, neuron specific enolase, HER2-neu, progastrin releas-ing peptide, S-100, and thyroglobulin. The results favour the use of tests which can identify pathological processes that may increase tumour marker concentrations.


Corresponding author: Jaume Trapé, Servei de Bioquímica, Departament de Diagnòstic Biològic, Althaia Xarxa Assistencial de Manresa, C/Dr Joan Soler 1-3, 08243 Manresa, Catalonia, Spain

Received: 2011-3-28
Accepted: 2011-7-25
Published Online: 2011-09-06
Published in Print: 2011-10-01

©2011 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Editorial
  2. Laboratory medicine: an essential partner in the care of cancer patients
  3. Reviews
  4. Circulating tumor cells as emerging tumor biomarkers in breast cancer
  5. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer
  6. Increased plasma concentrations of tumour markers in the absence of neoplasia
  7. Recent progress and clinical importance on pharmacogenetics in cancer therapy
  8. Genetics and Molecular Diagnostics
  9. Genotyping of the hemochromatosis HFE p.H63D and p.C282Y mutations by high-resolution melting with the Rotor-Gene 6000® instrument
  10. General Clinical Chemistry and Laboratory Medicine
  11. Mapping point-of-care performance using locally-smoothed median and maximum absolute difference curves
  12. The use of inflammatory markers as a method for discharging patients post hip or knee arthroplasty
  13. Significant elevation of plasma pentraxin 3 in patients with pelvic inflammatory disease
  14. Combined effects of coffee consumption and serum γ-glutamyltransferase on serum C-reactive protein in middle-aged and elderly Japanese men and women
  15. Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study
  16. Comparative evaluation of capillary zone electrophoresis and HPLC in the determination of carbohydrate-deficient transferrin
  17. Determinants of blood levels of some thrombogenic biomarkers in healthy Arab adolescent subjects
  18. Analytical performance of a multiplexed, bead-based cytokine detection system in small volume samples
  19. Diagnostic utility of a soluble cytokeratin 18 assay for gastrointestinal graft-vs.-host disease detection
  20. Cancer Diagnostics
  21. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer
  22. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells
  23. Serum APRIL, a potential tumor marker in pancreatic cancer
  24. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
  25. Infectious Diseases
  26. New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry
  27. Cardiovascular Diseases
  28. Association of a functional polymorphism in the MMP7 gene promoter with susceptibility to vulnerable carotid plaque in a Han Chinese Population
  29. Diabetes
  30. Glycated albumin may be a possible alternative to hemoglobin A1c in diabetic patients with anemia
  31. A simple micro-photometric method for urinary iodine determination
  32. Letters to the Editor
  33. Clinically needed sensitivity for very low levels of Factor XIII: not yet proven for a new functional assay
  34. Apolipoprotein A5-12238 T>C gene polymorphism and risk factors for metabolic syndrome in the Guo Shan Yao and the Han populations
  35. Congress Abstracts
  36. 10.1515/CCLM.2011.738
  37. 1st National Congress of Laboratory Medicine
Downloaded on 7.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.694/pdf
Scroll to top button